
Johnson & Johnson: shareholders and insiders
Price
$285.75
November 13, 2026Market cap $689B
What Ploutos Investor adds for Johnson & Johnson
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 15, 2025 to Nov 13, 2026, from their own Form 4 filings.
Bought on the market
$257.7K
1 person
Sold on the market
$154M
10 people
From Nov 15, 2025 to Nov 15, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 15, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $154M by 10 people
- 2025: bought $257.7K by 1 person, no sales
- 2026: no buys, sold $154M by 10 people
- Nov 12, 2026Elizabeth ForminardEVP, Chief Legal OfficerKind
- Nov 12, 2026Elizabeth ForminardEVP, Chief Legal OfficerKind
- Sep 2, 2026Timothy SchmidEVP, WW Chair, MedTechKind
- Sep 2, 2026Timothy SchmidEVP, WW Chair, MedTechKind
- Sep 2, 2026Timothy SchmidEVP, WW Chair, MedTechKind
- Sep 2, 2026Timothy SchmidEVP, WW Chair, MedTechKind
- Aug 17, 2026Jennifer L TaubertEVP, WWC. Innovative MedicineKind
- Aug 17, 2026Jennifer L TaubertEVP, WWC. Innovative MedicineKind
- Aug 13, 2026Joaquin DuatoCEO and Chairman of the BoardKind
- Aug 13, 2026Joaquin DuatoCEO and Chairman of the BoardKind
- Aug 13, 2026Joaquin DuatoCEO and Chairman of the BoardKind
- Aug 6, 2026Elizabeth ForminardEVP, Chief Legal OfficerKind
- Aug 6, 2026Elizabeth ForminardEVP, Chief Legal OfficerKind
- Aug 6, 2026Elizabeth ForminardEVP, Chief Legal OfficerKind
- Aug 5, 2026Joaquin DuatoCEO and Chairman of the BoardKind
- Aug 5, 2026Joaquin DuatoCEO and Chairman of the BoardKind
- Jul 20, 2026Vanessa BroadhurstEVP, Global Corp AffairsKind
- Jul 20, 2026Vanessa BroadhurstEVP, Global Corp AffairsKind
- Jul 20, 2026Vanessa BroadhurstEVP, Global Corp AffairsKind
- Jun 11, 2026Kathryn E WengelEVP, Chief TO and Risk OfficerKind
- Jun 11, 2026Kathryn E WengelEVP, Chief TO and Risk OfficerKind
- Feb 27, 2026Robert J DeckerVP Corporate ControllerKind
- Feb 20, 2026Timothy SchmidEVP, WW Chair, MedTechKind
- Feb 18, 2026Timothy SchmidEVP, WW Chair, MedTechKind
- Feb 18, 2026Timothy SchmidEVP, WW Chair, MedTechKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | Elizabeth ForminardEVP, Chief Legal Officer | 13.1K | $151.41 | $2.0M | Form 4 | |
| Nov 12, 2026 | Elizabeth ForminardEVP, Chief Legal Officer | 13.1K | $284.39 | $3.7M | Form 4 | |
| Sep 2, 2026 | Timothy SchmidEVP, WW Chair, MedTech | 11.1K | $131.94 | $1.5M | Form 4 | |
| Sep 2, 2026 | Timothy SchmidEVP, WW Chair, MedTech | 11.1K | $274.74 | $3.0M | Form 4 | |
| Sep 2, 2026 | Timothy SchmidEVP, WW Chair, MedTech | 22.5K | $151.41 | $3.4M | Form 4 | |
| Sep 2, 2026 | Timothy SchmidEVP, WW Chair, MedTech | 22.5K | $274.74 | $6.2M | Form 4 | |
| Aug 17, 2026 | Jennifer L TaubertEVP, WWC. Innovative Medicine | 15.0K | $115.67 | $1.7M | Form 4 | |
| Aug 17, 2026 | Jennifer L TaubertEVP, WWC. Innovative Medicine | 15.0K | $263.36 | $4.0M | Form 4 | |
| Aug 13, 2026 | Joaquin DuatoCEO and Chairman of the Board | 123.3K | $115.67 | $14M | Form 4 | |
| Aug 13, 2026 | Joaquin DuatoCEO and Chairman of the Board | 21.0K | $262.00 | $5.5M | Form 4 | |
| Aug 13, 2026 | Joaquin DuatoCEO and Chairman of the Board | 102.3K | $261.00 | $27M | Form 4 | |
| Aug 6, 2026 | Elizabeth ForminardEVP, Chief Legal Officer | 9,344 | $131.94 | $1.2M | Form 4 | |
| Aug 6, 2026 | Elizabeth ForminardEVP, Chief Legal Officer | 9,344 | $257.76 | $2.4M | Form 4 | |
| Aug 6, 2026 | Elizabeth ForminardEVP, Chief Legal Officer | 6,574 | $255.93 | $1.7M | Form 4 | |
| Aug 5, 2026 | Joaquin DuatoCEO and Chairman of the Board | 42.0K | $258.06 | $11M | Form 4 | |
| Aug 5, 2026 | Joaquin DuatoCEO and Chairman of the Board | 6,523 | $258.74 | $1.7M | Form 4 | |
| Jul 20, 2026 | Vanessa BroadhurstEVP, Global Corp Affairs | 11.1K | $129.51 | $1.4M | Form 4 | |
| Jul 20, 2026 | Vanessa BroadhurstEVP, Global Corp Affairs | 11.9K | $131.94 | $1.6M | Form 4 | |
| Jul 20, 2026 | Vanessa BroadhurstEVP, Global Corp Affairs | 23.1K | $251.27 | $5.8M | Form 4 | |
| Jun 11, 2026 | Kathryn E WengelEVP, Chief TO and Risk Officer | 10.0K | $115.67 | $1.2M | Form 4 | |
| Jun 11, 2026 | Kathryn E WengelEVP, Chief TO and Risk Officer | 10.0K | $241.15 | $2.4M | Form 4 | |
| Feb 27, 2026 | Robert J DeckerVP Corporate Controller | 4,075 | $247.87 | $1.0M | Form 4 | |
| Feb 20, 2026 | Timothy SchmidEVP, WW Chair, MedTech | 1,322 | $245.66 | $324.8K | Form 4 | |
| Feb 18, 2026 | Timothy SchmidEVP, WW Chair, MedTech | 13.6K | $244.20 | $3.3M | Form 4 | |
| Feb 18, 2026 | Timothy SchmidEVP, WW Chair, MedTech | 8,998 | $244.53 | $2.2M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 11, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by JNJ's officers and directors from 2006 up to November 14, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Vanguard Capital ManagementShare of class7.49%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Vanguard Capital Management | 7.49% | 181M | May 1, 2026 | 13G |
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- The Vanguard Group0.00%Mar 26, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Fairfax Financial (Watsa)In the quarter
- Bridgewater (Dalio)In the quarter-4.0%
- AQR CapitalIn the quarter-18%
- Citadel Advisors (Griffin)In the quarter-22%
- D.E. ShawIn the quarter-10%
- Millennium Mgmt (Englander)In the quarter+3.2%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Fairfax Financial (Watsa) | 73.4K | $19M | 0.71% | |
| Bridgewater (Dalio) | 669.1K | -4.0% | $170M | 0.70% |
| AQR Capital | 2.91M | -18% | $739M | 0.26% |
| Citadel Advisors (Griffin) | 1.50M | -22% | $381M | 0.22% |
| D.E. Shaw | 687.2K | -10% | $175M | 0.11% |
| Millennium Mgmt (Englander) | 594.1K | +3.2% | $151M | 0.10% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 0.70% of its shares outstanding were held short, -24.0% since the report before.
- Shares held short
- 16.77M
- 0.70%
- Since the report before22.07M on Sep 30, 2026
- -24.0%
- 2.0
- 8.52M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 24%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 14.53M
- Nov 15, 2023: Shares held short 13.19M
- Nov 30, 2023: Shares held short 15.00M
- Dec 15, 2023: Shares held short 15.40M
- Dec 29, 2023: Shares held short 12.47M
- Jan 12, 2024: Shares held short 15.01M
- Jan 31, 2024: Shares held short 12.30M
- Feb 15, 2024: Shares held short 10.96M
- Feb 29, 2024: Shares held short 14.85M
- Mar 15, 2024: Shares held short 15.84M
- Mar 28, 2024: Shares held short 15.94M
- Apr 15, 2024: Shares held short 16.56M
- Apr 30, 2024: Shares held short 17.67M
- May 15, 2024: Shares held short 17.43M
- May 31, 2024: Shares held short 19.93M
- Jun 14, 2024: Shares held short 19.56M
- Jun 28, 2024: Shares held short 21.17M
- Jul 15, 2024: Shares held short 17.99M
- Jul 31, 2024: Shares held short 18.85M
- Aug 15, 2024: Shares held short 19.81M
- Aug 30, 2024: Shares held short 21.13M
- Sep 13, 2024: Shares held short 23.03M
- Sep 30, 2024: Shares held short 19.74M
- Oct 15, 2024: Shares held short 18.66M
- Oct 31, 2024: Shares held short 18.11M
- Nov 15, 2024: Shares held short 17.48M
- Nov 29, 2024: Shares held short 18.54M
- Dec 13, 2024: Shares held short 17.57M
- Dec 31, 2024: Shares held short 16.46M
- Jan 15, 2025: Shares held short 17.20M
- Jan 31, 2025: Shares held short 18.76M
- Feb 14, 2025: Shares held short 18.35M
- Feb 28, 2025: Shares held short 23.10M
- Mar 14, 2025: Shares held short 24.87M
- Mar 31, 2025: Shares held short 19.15M
- Apr 15, 2025: Shares held short 21.02M
- Apr 30, 2025: Shares held short 19.68M
- May 15, 2025: Shares held short 22.80M
- May 30, 2025: Shares held short 19.22M
- Jun 13, 2025: Shares held short 16.33M
- Jun 30, 2025: Shares held short 15.82M
- Jul 15, 2025: Shares held short 18.27M
- Jul 31, 2025: Shares held short 17.14M
- Aug 15, 2025: Shares held short 18.52M
- Aug 29, 2025: Shares held short 18.84M
- Sep 15, 2025: Shares held short 22.05M
- Sep 30, 2025: Shares held short 18.18M
- Oct 15, 2025: Shares held short 20.63M
- Oct 31, 2025: Shares held short 19.53M
- Nov 14, 2025: Shares held short 20.12M
- Nov 28, 2025: Shares held short 23.91M
- Dec 15, 2025: Shares held short 23.97M
- Dec 31, 2025: Shares held short 20.43M
- Jan 15, 2026: Shares held short 21.33M
- Jan 30, 2026: Shares held short 19.56M
- Feb 13, 2026: Shares held short 20.77M
- Feb 27, 2026: Shares held short 25.09M
- Mar 13, 2026: Shares held short 23.33M
- Mar 31, 2026: Shares held short 22.27M
- Apr 15, 2026: Shares held short 19.67M
- Apr 30, 2026: Shares held short 22.35M
- May 15, 2026: Shares held short 23.04M
- May 29, 2026: Shares held short 23.41M
- Jun 15, 2026: Shares held short 26.69M
- Jun 30, 2026: Shares held short 26.58M
- Jul 15, 2026: Shares held short 27.43M
- Jul 31, 2026: Shares held short 25.41M
- Aug 14, 2026: Shares held short 21.59M
- Aug 31, 2026: Shares held short 21.67M
- Sep 15, 2026: Shares held short 21.19M
- Sep 30, 2026: Shares held short 22.07M
- Oct 15, 2026: Shares held short 16.77M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading31.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 31.5% of the shares in the reported trades were short sales, against 35.0% in the 14 before.
- Last 14 sessionsOct 27, 2026 – Nov 13, 2026
- 31.5%
- The 14 beforeOct 7, 2026 – Oct 26, 2026
- 35.0%
- Change
- -3.5 pts
- Short sales a dayon average, of 2.65M shares
- 832.4K
- More than atof 3,649 US-listed companies, same days
- 6%
- Median of alleight in ten from 34.6% to 63.4%
- 50.1%
- Short sales
- Oct 7, 2026: Short sales 30.6%
- Oct 8, 2026: Short sales 33.2%
- Oct 9, 2026: Short sales 31.1%
- Oct 12, 2026: Short sales 43.9%
- Oct 13, 2026: Short sales 48%
- Oct 14, 2026: Short sales 31.9%
- Oct 15, 2026: Short sales 27.6%
- Oct 16, 2026: Short sales 23.8%
- Oct 19, 2026: Short sales 41.7%
- Oct 20, 2026: Short sales 32%
- Oct 21, 2026: Short sales 24%
- Oct 22, 2026: Short sales 35%
- Oct 23, 2026: Short sales 34%
- Oct 26, 2026: Short sales 34.2%
- Oct 27, 2026: Short sales 43.6%
- Oct 28, 2026: Short sales 29.8%
- Oct 29, 2026: Short sales 33.4%
- Oct 30, 2026: Short sales 23.4%
- Nov 2, 2026: Short sales 25.6%
- Nov 3, 2026: Short sales 26.9%
- Nov 4, 2026: Short sales 22.3%
- Nov 5, 2026: Short sales 34.3%
- Nov 6, 2026: Short sales 37%
- Nov 9, 2026: Short sales 41.8%
- Nov 10, 2026: Short sales 20.5%
- Nov 11, 2026: Short sales 25.6%
- Nov 12, 2026: Short sales 45.6%
- Nov 13, 2026: Short sales 46.1%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Joaquin DuatoCEO and Chairman of the BoardDirectly276.0K
- Jennifer L TaubertEVP, WWC. Innovative MedicineDirectly194.5K
- Kathryn E WengelEVP, Chief TO and Risk OfficerDirectly114.3K
- Joseph J WolkExec VP, CFODirectly39.0K
- James D. SwansonEVP, CIODirectly25.7K
- Timothy SchmidEVP, WW Chair, MedTechDirectly25.4K
- Robert J DeckerVP Corporate ControllerDirectly23.7K
- Vanessa BroadhurstEVP, Global Corp AffairsDirectly23.0K
- Elizabeth ForminardEVP, Chief Legal OfficerDirectly17.0K
- John C ReedEVP, Innovative Medicine, R&DDirectly12.9K
- John G MorikisDirectorDirectly1,849
- Mark A WeinbergerDirectorDirectly1,000
- Eugene A. WoodsDirectorDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Joaquin DuatoCEO and Chairman of the Board | 276.0K | 79.6K | Aug 13, 2026 | Form 4 |
| Jennifer L TaubertEVP, WWC. Innovative Medicine | 194.5K | – | Aug 17, 2026 | Form 4 |
| Kathryn E WengelEVP, Chief TO and Risk Officer | 114.3K | – | Jun 11, 2026 | Form 4 |
| Joseph J WolkExec VP, CFO | 39.0K | – | Feb 17, 2026 | Form 4 |
| James D. SwansonEVP, CIO | 25.7K | – | Feb 17, 2026 | Form 4 |
| Timothy SchmidEVP, WW Chair, MedTech | 25.4K | – | Sep 2, 2026 | Form 4 |
| Robert J DeckerVP Corporate Controller | 23.7K | – | Feb 27, 2026 | Form 4 |
| Vanessa BroadhurstEVP, Global Corp Affairs | 23.0K | – | Jul 20, 2026 | Form 4 |
| Elizabeth ForminardEVP, Chief Legal Officer | 17.0K | – | Nov 12, 2026 | Form 4 |
| John C ReedEVP, Innovative Medicine, R&D | 12.9K | – | Feb 17, 2026 | Form 4 |
| John G MorikisDirector | 1,849 | – | Nov 26, 2025 | Form 4 |
| Mark A WeinbergerDirector | 1,000 | – | Dec 12, 2024 | Form 4 |
| Eugene A. WoodsDirector | – | 250 | Apr 30, 2024 | Form 4 |
A lower bound: it counts only the 13 officers and directors with a market trade since Nov 16, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Peter FasoloExecutive Vice President, Chief Human Resources OfficerWhat happenedAdoptedAug 31, 2023Shares25.0K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Peter FasoloExecutive Vice President, Chief Human Resources Officer | AdoptedAug 31, 2023 | 456 days | 25.0K | 10-Q |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$33M
Actually paid: $68M
$12M
Actually paid: $25M
$152
Peers: $189
Annual relative total shareholder return
From the proxy statement (DEF 14A) of Mar 11, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026Apr 28, 2026For94.7%
- 2025Apr 30, 2025For91.6%
- 2024Apr 29, 2024For90.5%
- 2023May 1, 2023For93.2%
- 2022Apr 29, 2022For86.0%
- 2021Apr 26, 2021For56.7%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026Apr 28, 2026 | 94.7% | 1.64B | 91.77M | 9.61M | 314M | 8-K |
| 2025Apr 30, 2025 | 91.6% | 1.56B | 142M | 7.36M | 324M | 8-K |
| 2024Apr 29, 2024 | 90.5% | 1.51B | 159M | 9.37M | 338M | 8-K |
| 2023May 1, 2023 | 93.2% | 1.69B | 123M | 11.08M | 353M | 8-K |
| 2022Apr 29, 2022 | 86.0% | 1.58B | 258M | 11.48M | 346M | 8-K |
| 2021Apr 26, 2021 | 56.7% | 987M | 753M | 90.90M | 362M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund10.64%
- IYHiShares U.S. Healthcare ETFWeight in the fund10.17%
- VHTVanguard Health Care Index FundWeight in the fund8.75%
- IXJiShares Global Healthcare ETFWeight in the fund7.04%
- SPMOInvesco S&P 500 Momentum ETFWeight in the fund4.65%
- MTUMiShares MSCI USA Momentum Factor ETFWeight in the fund3.54%
- DGROiShares Core Dividend Growth ETFWeight in the fund3.07%
- MGVVanguard Morningstar Mega Cap Value Index FundWeight in the fund2.96%
- DIADIAWeight in the fund2.90%
- VIGVanguard Dividend Appreciation Index FundWeight in the fund2.67%
59 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 4,201
- Q4 2025: Managers 4,549
- Q1 2026: Managers 4,655
- Q2 2026: Managers 4,681
Institutional investors by quarter
The fund managers holding JNJ, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 4,681 managers held 1.80B shares, worth $457B. During the quarter 219 opened a position, 193 closed one, 1,941 added and 1,853 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter-0.6%
- Vanguard Capital ManagementIn the quarter+0.4%
- State StreetIn the quarter+0.2%
- Vanguard Portfolio ManagementIn the quarter+1.3%
- Geode Capital ManagementIn the quarter-0.1%
- JPMorgan ChaseIn the quarter-7.6%
- Morgan StanleyIn the quarter+0.2%
- Norges BankIn the quarter-4.9%
- State Farm Mutual Automobile InsuranceIn the quarter
- Northern TrustIn the quarter-1.8%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 212M | -0.6% | $53.9B |
| Vanguard Capital Management | 157M | +0.4% | $39.9B |
| State Street | 134M | +0.2% | $34.0B |
| Vanguard Portfolio Management | 64.37M | +1.3% | $16.3B |
| Geode Capital Management | 59.09M | -0.1% | $15.0B |
| JPMorgan Chase | 58.30M | -7.6% | $15.1B |
| Morgan Stanley | 44.81M | +0.2% | $11.4B |
| Norges Bank | 31.83M | -4.9% | $8.1B |
| State Farm Mutual Automobile Insurance | 31.59M | $8.0B | |
| Northern Trust | 28.79M | -1.8% | $7.3B |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Johnson & Johnson's filings show?
Who buys and sells is one part of Johnson & Johnson's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have JNJ's insiders bought or sold?
From Jun 11, 2026 to Nov 13, 2026 Johnson & Johnson's insiders bought 0 and sold $74M of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold JNJ?
6 of the managers we track held the shares on Jun 30, 2026. The largest position was AQR Capital's, worth $739M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.